Primary Recipient

NOVADIGM THERAPEUTICS, INC.

Amount

$1,989,750.00

Award Date

9/17/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

Our Specific Aims are: 1. To establish Good Manufacturing Practice for the rAls3p-N vaccine candidate. GMP will be established by a contracting organization. Financing for GMP will occur over two calendar years. The GMP process will include technologic

Recipients Connected to Award

Recipient	Role	Amount
NOVADIGM THERAPEUTICS, INC.	Primary recipient	$1,299,178.00
LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER	Sub-recipient	$690,572.00

Vendors Connected to Award

Vendor	Role	Amount
Althea Technologies, Inc.	Primary vendor	$36,750.00
MPI Research, Inc.	Primary vendor	$27,000.00
Althea Technologies, Inc.	Primary vendor	$76,700.00
Advanced BioScience Laboratories, Inc.	Primary vendor	$35,113.00
Althea Technologies, Inc.	Primary vendor	$33,000.00